MA54932A - Traitement contre le cancer - Google Patents

Traitement contre le cancer

Info

Publication number
MA54932A
MA54932A MA054932A MA54932A MA54932A MA 54932 A MA54932 A MA 54932A MA 054932 A MA054932 A MA 054932A MA 54932 A MA54932 A MA 54932A MA 54932 A MA54932 A MA 54932A
Authority
MA
Morocco
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
MA054932A
Other languages
English (en)
Inventor
Anjali Narayan Avadhani
Porre Peter Marie Z De
Anne Elizabeth O'hagan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA54932A publication Critical patent/MA54932A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054932A 2019-02-12 2020-02-11 Traitement contre le cancer MA54932A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19176575 2019-05-24

Publications (1)

Publication Number Publication Date
MA54932A true MA54932A (fr) 2021-12-22

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054932A MA54932A (fr) 2019-02-12 2020-02-11 Traitement contre le cancer

Country Status (16)

Country Link
US (1) US20220168298A1 (fr)
EP (1) EP3923942A1 (fr)
JP (2) JP2022521173A (fr)
KR (1) KR20210126654A (fr)
CN (1) CN113423402A (fr)
AU (1) AU2020223467B2 (fr)
BR (1) BR112021015686A2 (fr)
CA (1) CA3126959A1 (fr)
IL (1) IL285466A (fr)
JO (1) JOP20210216A1 (fr)
MA (1) MA54932A (fr)
MX (1) MX2021009670A (fr)
PH (1) PH12021551949A1 (fr)
SG (1) SG11202107850VA (fr)
TW (1) TWI863962B (fr)
WO (1) WO2020165181A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
AU2021396397A1 (en) * 2020-12-11 2023-07-27 Erasca, Inc. Combination therapies for the treatment of cancer
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170104A (es) * 2014-09-26 2017-05-31 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
JO3695B1 (ar) * 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
EP3365335B1 (fr) * 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
HRP20230697T1 (hr) * 2017-02-06 2023-10-13 Janssen Pharmaceutica Nv Liječenje karcinoma
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
PT3576740T (pt) * 2017-12-20 2023-08-18 Janssen Pharmaceutica Nv Tratamento de cancro

Also Published As

Publication number Publication date
MX2021009670A (es) 2021-09-08
JOP20210216A1 (ar) 2023-01-30
PH12021551949A1 (en) 2022-07-18
TW202045173A (zh) 2020-12-16
AU2020223467A1 (en) 2021-08-05
JP2022521173A (ja) 2022-04-06
IL285466A (en) 2021-09-30
BR112021015686A2 (pt) 2021-10-26
TWI863962B (zh) 2024-12-01
US20220168298A1 (en) 2022-06-02
KR20210126654A (ko) 2021-10-20
SG11202107850VA (en) 2021-08-30
EP3923942A1 (fr) 2021-12-22
CN113423402A (zh) 2021-09-21
AU2020223467B2 (en) 2025-12-04
CA3126959A1 (fr) 2020-08-20
JP2026016402A (ja) 2026-02-03
WO2020165181A1 (fr) 2020-08-20

Similar Documents

Publication Publication Date Title
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
MA47408A (fr) Traitement du cancer
PL3197456T3 (pl) Leczenie nowotworów
IL291170A (en) Treatment of hr deficient cancer
MA52627A (fr) Traitement du cancer
DK3768830T5 (da) Cancerterapi
GB201903546D0 (en) Cancer treatment
EP3606531A4 (fr) Méthodes de traitement du cancer
DK3576740T3 (da) Cancerbehandling
IL281845A (en) Combination therapy for the treatment of cancer
EP3733175A4 (fr) Traitement du cancer
EP3576791A4 (fr) Traitement du cancer à médiation par calréticuline
IL308399A (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
EP3737383A4 (fr) Traitement synergique du cancer
IL287652A (en) Cancer treatment
EP3713576A4 (fr) Méthodes de traitement du cancer
EP3484477A4 (fr) Traitement du cancer
EP4025203A4 (fr) Traitement du cancer
IL285466A (en) Cancer treatment
IL281281A (en) Combination therapy for the treatment of prostate cancer
EP3664851A4 (fr) Combinaisons pour le traitement du cancer
EP4081250A4 (fr) Traitement anti-allergique
EP4401721A4 (fr) Traitement contre le cancer
EP3723765A4 (fr) Méthodes de traitement du cancer